Vero

Laverock Therapeutics, a UK-based gene editing company, has announced new in vivo programmes focused on oncology and genetic medicine, meaning its therapies would be delivered directly into patients' bodies rather than editing cells outside them. The move marks an expansion of the company's pipeline, though detailed trial plans and timelines have not yet been outlined.